Best Practice & Research Clinical Obstetrics & Gynaecology
Volume 16, Issue 4 , Pages 513-527 , August 2002

Clinical management potential tumours of low malignancy

References 

    REFERENCES
  1. Taylor HC. Malignant and semimalignant tumors of the ovary. Surgical Gynecology & Obstetrics. 1929;48:204–230
  2. Acta Obstetricia et Gynecologica Scandinavica. 1971;50:1–7
  3. Serov SF, Scully RE, Solvin LH. International histologic classification of tumors. No. 9: Histologic typing of ovarian tumors. Geneva: World Health Organization; 1973; p. 37–41
  4. Tamakoshi K, Kikkawa F, Shibata K. Clinical value of CA125, CA19-9, CEA, CA72-4 and TPA in borderline ovarian tumor. Gynecologic Oncology. 1996;62:67–72
  5. Ochiai K, Shinozaki H, Takada A. A retrospective study of 1069 epithelial borderline malignancies of the ovary treated in Japan. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1998;17:A1429
  6. Tazelaar HD, Bostwick DG, Ballon SC. Conservative treatment of borderline ovarian tumors. Obstetrics & Gynecology. 1985;66:417–422
  7. Lim-Tan SK, Cajigas HE, Scully RE. Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases. Obstetrics & Gynecology. 1988;72:775–781
  8. Bostwick DG, Tazelaar HD, Ballon SC. Ovarian epithelial tumors of borderline malignancy: A clinical and pathologic study of 109 cases. Cancer. 1986;58:2052–2065
  9. Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors: Histologic features and prognosis. Cancer. 1988;62:2212–2222
  10. Leake JF, Currie JL, Rosenshein NB, Woodruff JD. Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecologic Oncology. 1992;47:150–158
  11. Gershenson DM, Silva EG, Levy L. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer. 1998;82:1096–1103
  12. Hopkins MP, Morley GW. The second-look operation and surgical re-exploration in ovarian tumor of low malignant potential. Obstetrics & Gynecology. 1989;74:375–378
  13. Yazigi R, Sandstad J, Munoz AK. Primary staging in ovarian tumors of low malignant potential. Gynecologic Oncology. 1988;31:402–408
  14. Snider DD, Stuart G CE, Nation JG, Robertson DI. Evaluation of surgical staging in stage I low malignant potential ovarian tumors. Gynecologic Oncology. 1991;40:129–132
  15. Lin PS, Gershenson DM, Bevers MW. The current status of surgical staging of ovarian serous borderline tumors. Cancer. 1999;85:905–911
  16. Rice LW, Berkowitz RS, Mark D. Epithelial ovarian tumors of borderline malignancy. Gynecologic Oncology. 1990;39:195–198
  17. Casey AC, Bell DA, Lage JM. Epithelial ovarian tumors of borderline malignancy: long-term follow-up. Gynecologic Oncology. 1993;50:316–322
  18. Barnhill DR, Kurman RJ, Brady MF. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. Journal of Clinical Oncology. 1995;13:2752–2756
  19. Hart WK, Norris HJ. Borderline and malignant mucinous tumors of the ovary: histologic criteria and clinical behavior. Cancer. 1973;31:1031–1045
  20. Silva EG, Tornos C, Zhuang Z. Tumor recurrence in stage I ovarian serous neoplasms of low malignant potential. International Journal of Gynecologic Pathology. 1998;17:1–6
  21. Gershenson DM, Silva EG, Tortolero-Luna G. Ovarian serous borderline tumors with noninvasive peritoneal implants. Cancer. 1998;83:2157–2163
  22. Kliman L, Rome RM, Fortune DW. Low malignant potential tumors of the ovary: a study of 76 cases. Obstetrics & Gynecology. 1986;68:338–344
  23. Manchul LA, Simm J, Levin W. Borderline epithelial ovarian tumors: a review of 81 cases with an assessment of the impact of treatment. International Journal of Radiation Oncology, Biology and Physics. 1992;22:867–874
  24. Russell P. Borderline epithelial tumours of the ovary: a conceptual dilemma. Clinical Obstetrics & Gynecology. 1984;11:259–277
  25. Michael H, Roth LM. Invasive and noninvasive implants in ovarian serous tumors of low malignant potential. Cancer. 1986;57:1240–1247
  26. McCaughey W TE, Kirk ME, Lester W, Dardick I. Peritoneal epithelial lesions associated with proliferative serous tumours of ovary. Histopathology. 1984;8:195–208
  27. De Nictolis M, Montironi R, Tommasoni S. Serous borderline tumors of the ovary: a clinicopathologic, immunohistochemical, and quantitative study of 44 cases. Cancer. 1992;70:152–160
  28. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types: a clinicopathologic study of 65 advanced stage cases. American Journal of Surgical Pathology. 1996;20:1331–1345
  29. Zanetta G, Rota S, Chiari S. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. Journal of Clinical Oncology. 2001;19:2658–2664
  30. Kennedy AW, Hart WR. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors): a long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Cancer. 1996;78:278–286
  31. Tavassoli FA. Serous tumor of low malignant potential with early stromal invasion (serous LMP with microinvasion). Modern Pathology. 1988;1:407–414
  32. Bell DA, Scully RE. Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases. Human Pathology. 1990;21:397–403
  33. Nayar R, Siriaunkgul S, Robbins KM. Microinvasion in low malignant potential tumors of the ovary. Human Pathology. 1996;27:521–527
  34. Buttin BM, Herzog TJ, Powell MA. Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstetrics & Gynecology. 2002;99:11–17
  35. Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary: a distinctive low-grade carcinoma related to serous borderline tumors. American Journal of Surgical Pathology. 1996;20:1319–1330
  36. Eichhorn JH, Bell DA, Young RH, Scully RE. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns. American Journal of Surgical Pathology. 1999;23:397–409
  37. Deavers MT, Tortolero-Luna G, Malpica A. Micropapillary and cribriform patterns and microinvasion in ovarian serous borderline tumors (SBT): a study of 99 advanced stage cases. Gynecologic Oncology. 2000;26:280
  38. Fort MG, Pierce VK, Saigo PE. Evidence for the efficacy of adjuvant therapy in epithelial ovarian tumors of low malignant potential. Gynecologic Oncology. 1989;32:269–272
  39. Chambers JT, Merino MJ, Kohorn EI, Schwartz PE. Borderline ovarian tumors. American Journal of Obstetrics & Gynecology. 1988;159:1088–1094
  40. Nation JG, Krepart GV. Ovarian carcinoma of low malignant potential: staging and treatment. American Journal of Obstetrics and Gynecology. 1986;154:290–293
  41. Nikrui N. Survey of clinical behavior of patients with borderline epithelial tumors of the ovary. Gynecologic Oncology. 1981;12:107–119
  42. Friedlander ML, Russell P, Taylor IW. Flow cytometric analysis of cellular DNA content as an adjunct to the diagnosis of ovarian tumours of borderline malignancy. Pathology. 1984;16:301–306
  43. Erhardt K, Auer G, Björkholm E. Prognostic significance of nuclear DNA content in serous ovarian tumors. Cancer Research. 1984;44:2198–2202
  44. Dietel M, Arps H, Rohlff A. Nuclear DNA content of borderline tumors of the ovary: Correlation with histology and significance for prognosis. Virchows Archiv (A Pathol Anat). 1986;409:829–836
  45. Fu YS, Ro J, Reagan JW. Nuclear deoxyribonucleic acid heterogeneity of ovarian borderline malignant serous tumor. Obstetrics & Gynecology. 1986;67:478–482
  46. Kühn W, Kaufmann M, Feichter GE. DNA flow cytometry, clinical and morphological parameters as prognostic factors for advanced malignant and borderline ovarian tumors. Gynecologic Oncology. 1987;33:360–367
  47. Kaern J, Tropé CG, Kjørstad KE. Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary. Gynecologic Oncology. 1990;38:452–457
  48. Weiss RR, Richart RM, Okagaki T. DNA content of mucinous tumors of the ovary. American Journal of Obstetrics and Gynecology. 1969;107:409–424
  49. Iversen OE, Skaarland E. Ploidy assessment of benign and malignant ovarian tumors by flow cytometry: a clinicopathologic study. Cancer. 1987;60:82–87
  50. Klemi PJ, Joensuu H, Kilholma P, Maenpaa J. Clinical significance of abnormal nuclear DNA content in serous ovarian tumors. Cancer. 1988;62:2005–2010
  51. Olinici CD, Caluser I. DNA nuclear content in borderline ovarian tumors. Morphology/Embryology. 1988;24:49–52
  52. Andersen, E, S, Nielsen, K, Nielsen, R, H, Borderline epithelial tumours of the ovary
  53. Enomoto T, Weghorst CM, Inoue M. K- ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. American Journal of Pathology. 1991;139:777–785
  54. Mok S CH, Bell DA, Knapp RC. Mutation of K- ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Research. 1993;53:1489–1492
  55. Ichikawa Y, Nishida M, Suzuki H. Mutation of K- ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Research. 1994;54:33–35
  56. Wertheim I, Muto MG, Welch W. p53 gene mutation in human borderline epithelial ovarian tumor. Journal of the National Cancer Institute. 1994;86:1549–1551
  57. Kupryjanczyk J, Bell DA, Dimeo D. p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Human Pathology. 1995;26:387–392
  58. Henriksen R, Strang P, Wilander E. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecologic Oncology. 1994;53:301–306
  59. Kupryjanczyk J, Bell DA, Yandell DW. p53 expression in ovarian borderline tumors and stage I carcinomas. American Journal of Clinical Pathology. 1994;102:671–676
  60. Berchuck A, Kohler MF, Hopkins MP. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecologic Oncology. 1994;52:232–236
  61. Marcelli AR, Demopoulos RI, Goswami S, Mittal KR. Comparison of I and MIB1 expression in benign and borderline areas of ovarian serous tumors. International Journal of Gynecologic Pathology. 1996;15:39–44
  62. Lee JH, Kang YS, Park SY. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Cancer Genetics and Cytogenetics. 1995;85:43–50
  63. Koshiyama M, Konishi I, Mandai M. Immunohistochemical analysis of p53 protein and 72kDa heat shock protein (HSP72) expression in ovarian carcinomas: correlation with clinicopathology and sex steroid receptor status. Virchows Archiv A Pathol Anat. 1995;425:603–609
  64. Klemi PJ, Takahashi S, Joensuu H. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. International Journal of Gynecologic Pathology. 1994;13:228–233
  65. Kiyokawa T. Alteration of p53 in ovarian cancer: its occurrence and maintenance in tumor progression. International Journal of Gynecologic Pathology. 1994;13:311–316
  66. Eltabbakh GH, Belinson JL, Kennedy AW. p53 and HER-2/ neu overexpression in ovarian borderline tumors. Gynecologic Oncology. 1997;65:218–224
  67. Gershenson DM, Deavers M, Diaz S. Prognostic significance of p53 expression in advanced stage ovarian serous borderline tumors. Clinical Cancer Research. 1999;5:4053–4058
  68. Lu KH, Bell DA, Welch WR. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Research. 1998;58:2328–2330
  69. Gu J, Roth LM, Younger C. Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. Journal of the National Cancer Institute. 2001;93:1147–1152
  70. Ortiz BH, Ailawadi M, Colitti C. Second primary or recurrence? Comparative patterns of p53 and K- ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Research. 2001;61:7264–7267
  71. Gotlieb WH, Flikker S, Davidson B. Borderline tumors of the ovary: fertility treatment, conservative management, and pregnancy outcome. Cancer. 1998;82:141–146
  72. Morris RT, Gershenson DM, Silva EG. Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstetrics & Gynecology. 2000;95:541–547
  73. Crispens MA, Bodurka D, Deavers M. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstetrics & Gynecology. 2002;99:3–10

PII: S1521-6934(02)90308-1

doi: 10.1053/beog.2002.0308

Best Practice & Research Clinical Obstetrics & Gynaecology
Volume 16, Issue 4 , Pages 513-527 , August 2002

Article Tools